Skin-Applied Melanoma Peptide Vaccine Triggers Strong Immune Response in 83-86% of Patients | Research

The takeaway

A transdermal melanoma peptide vaccine in DMSO achieved CD8+ T cell responses in 83-86% of patients — far higher than the 14-29% with traditional injection methods — with 67% ten-year overall survival.

83-86% immune response via skin
Transdermal DMSO delivery achieved 3-6x higher CD8+ T cell response rates than traditional IFA injection for melanoma peptide vaccination

What the researchers found

Twenty-eight melanoma patients were randomized to four adjuvant groups for transdermal peptide vaccination (12 melanoma peptides + tetanus helper peptide + GM-CSF). CD8+ T cell responses to transdermal vaccination in DMSO occurred in 83% (group 3) and 86% (group 4) of participants, dramatically exceeding responses with IFA: 29% (group 1) and 14% (group 2). CD4+ T cell responses to tetanus peptide occurred in 61% overall, with large durable responses in DMSO groups. However, 5/7 patients receiving DMSO + imiquimod developed severe rash, one dose-limiting. Ten-year overall survival was 67% and disease-free survival was 44%.

Why it matters

This trial proves that cancer peptide vaccines can be delivered through the skin, achieving far higher immune response rates than traditional injection methods. If validated in larger trials, transdermal vaccination could make cancer immunization less invasive, more effective, and more accessible — potentially transforming how therapeutic cancer vaccines are administered.

The numbers in context

N=28; 12 peptides + tetanus helper; DMSO CD8+ response 83-86%; IFA 14-29%; 10yr OS 67%; DFS 44%; 5/7 severe rash with imiquimod

How the study worked

Phase I/II randomized clinical trial in 28 melanoma patients across four adjuvant groups. Peptides applied topically on days 1, 8, and 15, then injected intradermally/subcutaneously every 3 weeks for 6 cycles. Immune responses measured by ELIspot assay for CD8+ and CD4+ T cell responses. Toxicities recorded and 10-year survival outcomes tracked.

Who was studied

28 melanoma patients randomized to 4 adjuvant groups

What this study cannot tell us

Small trial (n=28) without an unvaccinated control group. The 10-year survival cannot be directly attributed to vaccination. Imiquimod caused unacceptable toxicity in most recipients. The DMSO delivery mechanism needs further pharmacokinetic characterization. The trial enrolled patients across a range of melanoma stages, and the small group sizes limit statistical comparisons between adjuvants.

How to read the evidence

This is a small Phase I/II randomized trial (n=28) providing proof of concept with 10-year follow-up. While the immune response data is striking and survival is encouraging, the small sample size, lack of unvaccinated controls, and imiquimod toxicity issues limit the strength of conclusions.

When this study was published

Published in 2021 with 10-year survival data, this study represents a mature dataset from an early exploration of transdermal cancer vaccination that remains relevant to current vaccine development strategies.

The bigger picture

Peptide-based cancer vaccines have shown immunogenicity in many trials but have struggled with clinical efficacy, partly due to suboptimal delivery. This study suggests the delivery method matters enormously — targeting skin Langerhans cells via transdermal application may unlock the potential that injectable peptide vaccines have not fully realized. Combined with the checkpoint immunotherapy revolution, improved peptide vaccination could become a powerful combination approach.

Questions still open

Could transdermal peptide vaccination combined with checkpoint inhibitors produce synergistic anti-cancer effects?
Can the imiquimod toxicity be avoided by using alternative TLR agonists or lower doses in the transdermal formulation?
Would this approach work for peptide vaccines targeting other cancer types beyond melanoma?

Common questions

How can a vaccine be applied through the skin instead of injected?

The skin contains specialized immune cells called Langerhans cells right at the surface. By dissolving cancer peptides in DMSO (a chemical that helps substances penetrate skin), the vaccine reaches these cells directly. This proved more effective at triggering immune responses than injecting the same peptides deeper into tissue.

Does the 67% ten-year survival mean the vaccine cured melanoma?

Not necessarily. While 67% ten-year survival is encouraging, this small trial had no unvaccinated control group, so the survival benefit cannot be definitively attributed to the vaccine. The strong immune responses suggest the vaccine may have contributed, but larger controlled trials are needed to prove it.

Read the original research

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.

Journal for immunotherapy of cancer, 9(5)

View on PubMed ↗Publisher’s paper ↗

Citation

Meneveau, Max O; Petroni, Gina R; Salerno, Elise P; Lynch, Kevin T; Smolkin, Mark; Woodson, Elizabeth; Chianese-Bullock, Kimberly A; Olson, Walter C; Deacon, Donna; Patterson, James W; Grosh, William W; Slingluff, Craig L. (2021). Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.. Journal for immunotherapy of cancer, 9(5). https://doi.org/10.1136/jitc-2020-002214